Trevi Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Trevi Therapeutics, Inc. (TRVI) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $8.04 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $8.04.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $7.29.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $3.99.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $3.88.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $8.04 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.29 10-Q · filed 2026-05-05 |
| 2025-12-31 | $3.99 10-K · filed 2026-03-17 |
| 2025-09-30 | $3.88 10-Q · filed 2025-11-13 |
| 2025-06-30 | $3.57 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.26 10-Q · filed 2025-05-08 |
| 2024-12-31 | $2.48 10-K · filed 2025-03-18 |
| 2024-09-30 | $2.47 10-Q · filed 2024-11-06 |
| 2024-06-30 | $2.33 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.27 10-Q · filed 2024-05-07 |
| 2023-12-31 | $2.20 10-K · filed 2024-03-20 |
| 2023-09-30 | $2.20 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.22 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.27 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.84 10-K · filed 2023-03-16 |
| 2022-09-30 | $1.99 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.09 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.39 10-Q · filed 2022-05-12 |
| 2021-12-31 | $3.94 10-K · filed 2022-03-17 |
| 2021-09-30 | $4.03 10-Q · filed 2021-11-10 |
| 2021-06-30 | $4.24 10-Q · filed 2021-08-12 |
| 2021-03-31 | $4.77 10-Q · filed 2021-05-13 |
| 2020-12-31 | $6.44 10-K · filed 2021-03-25 |
| 2020-09-30 | $6.73 10-Q · filed 2020-11-12 |
| 2020-06-30 | $6.94 10-Q · filed 2020-08-13 |
| 2020-03-31 | $7.40 10-Q · filed 2020-05-07 |
| 2019-12-31 | $8.35 10-K · filed 2020-03-16 |
| 2019-09-30 | $8.27 10-Q · filed 2019-11-14 |
| 2019-06-30 | $8.19 10-Q · filed 2019-08-12 |
| 2019-03-31 | $5.51 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |